The Therapeutic Goods Administration (TGA) has released its latest update on regulatory decisions affecting Australian therapeutic goods manufacturing, announcing changes to manufacturing licences held by manufacturers across the country.
According to the TGA, the July 2026 update includes the granting of three manufacturing licences, the suspension of six manufacturing licences, and the revocation of one manufacturing licence.
The decisions are reflected in the regulator’s list of Australian manufacturers licensed by the TGA.
The TGA said the latest regulatory actions relate to manufacturers of therapeutic goods operating under Australia’s licensing framework. Details of each decision are available through the regulator’s published lists covering granted, suspended and revoked manufacturing licences.
In its announcement, the TGA said the update includes “the granting of 3 manufacturing licences,” “the suspension of 6 manufacturing licences,” and “the revocation of 1 manufacturing licence.”
The regulator publishes updates to its list of licensed Australian manufacturers to reflect decisions made under its regulatory responsibilities for therapeutic goods manufacturing.
The TGA did not provide further details in the announcement regarding the reasons for the individual licensing decisions.
Additional information on the affected manufacturers is available through the regulator’s published licence decision lists.
